Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

Phase 1 Recruiting 48 enrolled Kiromic BioPharma Inc. Stiris Research Inc · collab

NaSequentialOpen-labelTreatment

Summary

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.

Timeline

Start: 2023-11-07
Primary completion: 2025-10
Completion: 2026-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KB-GDT-01	Cell therapy	4e+08 cells	Intravenous
Subject	KB-GDT-01	Cell therapy	8e+08 cells	Intravenous
Subject	KB-GDT-01	Cell therapy	1.6e+09 cells	Intravenous

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

Summary

Timeline

Drugs

Indications